Ultrafast 30-min infusion of a rituximab biosimilar (Truxima).

Autor: Pérez-Persona E; Department of Haematology Complejo Hospitalario de Navarra Pamplona Spain., Cuevas Palomares L; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain.; Osakidetza (OSI Araba) Hospital Universitario de Álava (Department of Haematology) Vitoria-Gasteiz Spain., Unamunzaga Cilaurren A; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain., Gutiérrez López de Ocáriz X; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain., Buendía Ureña B; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain., Vega González de Viñaspre A; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain., Benito Ibarrondo B; Osakidetza (OSI Araba) Hospital Universitario de Álava (Day-care Unit) Vitoria-Gasteiz Spain., Molinillo Fernández MC; Osakidetza (OSI Araba) Hospital Universitario de Álava (Day-care Unit) Vitoria-Gasteiz Spain., Cordero Osúa A; Osakidetza (OSI Araba) Hospital Universitario de Álava (Day-care Unit) Vitoria-Gasteiz Spain., Benítez Delgado B; Osakidetza (OSI Araba) Hospital Universitario de Álava (Day-care Unit) Vitoria-Gasteiz Spain., García Albás JJ; Osakidetza (OSI Araba) Hospital Universitario de Álava (Department of Pharmacy) Vitoria-Gasteiz Spain., Andrés Moralejo MÁ; Osakidetza (OSI Araba) Hospital Universitario de Álava (Department of Pharmacy) Vitoria-Gasteiz Spain., Guinea de Castro JM; Bioaraba (Onco-Haematology Group) Vitoria-Gasteiz Spain.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2023 Oct 17; Vol. 4 (4), pp. 1196-1199. Date of Electronic Publication: 2023 Oct 17 (Print Publication: 2023).
DOI: 10.1002/jha2.812
Abstrakt: In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, and reduce the day-care hospital stays.
Competing Interests: EPP: Presentation: Amgen, Sanofi Kern. Travel and accomodation: Abbvie, Sanofi. XGO: Advisory boards for Janssen, BMS, Sanofi, GSK, Amgen, Astrazeneca, Gilead, JazzPharma. Presentations: Janssen, BMS, Sanofi, GSK, Amgen, SOBI, Abbvie. JMGC: Presentations: Kern. Advisory board for Novartis, Pfizer, and Alexion. LCP, BBU, AUC, AVG, BBI, MCMF, ACO, BBD, JJGA, and MAAM declare not conflict of interest.
(© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: